Literature DB >> 15375556

A telomerase-immortalized primary human prostate cancer clonal cell line with neoplastic phenotypes.

Yongpeng Gu1, Kee-Hong Kim, Daejin Ko, Keiichiro Nakamura, Yutaka Yasunaga, Judd W Moul, Shiv Srivastava, Paul Arnstein, Johng S Rhim.   

Abstract

Understanding of molecular genetic mechanisms underlying prostate carcinogenesis would be greatly advanced by in vitro models of prostate tumors representing primary tumors. We have successfully established a neoplastic immortalized human prostate epithelial (HPE) clonal culture derived from a primary tumor of a prostate cancer patient (RC-58T) with hTERT, the catalytic subunit of telomerase. The early passage RC-58T cells derived from a radical prostatectomy specimen of a 52-year-old white male patient was transduced through infection with a retrovirus vector expressing the hTERT for the establishment of the RC-58T/hTERT cell line. One clonal line, soft-agar derived from the RC-58T/hTERT cell line, was isolated and further characterized phenotypically and genetically. These clonal (RC-58T/hTERT SA#4) cells are currently growing well at passage 70 and exhibit transformed morphology. The RC-58T/hTERT SA#4 line expressed a high level of telomerase activity and showed anchorage-independent growth in soft agar. The clonal line like the untransduced RC-58T cells (passage 3) expressed prostate specific antigen (PSA), androgen receptor (AR), prostate stem cell antigen (PSCA), and an androgen-regulated prostate specific gene NKX3.1, P16, and cytokeratin (CK) 8. Growth is slightly stimulated by dihydrotestosterone (DHT), and lyates are immunoreactive with AR antibody by Western blot analysis. More importantly, this clonal line produced adenocarcinomas when transplanted into SCID mice. A number of chromosome alterations were observed including the loss of chromosome Y, 1q, 2p, 3p, 4q, 8p, 11p, 14p, 17p and 18q. Our results demonstrate that this primary tumor-derived HPE cell line retained its neoplastic phenotypes and its prostate specific markers and should allow elucidating molecular and genetic alterations involved in prostate cancer. This is the first documented case of an AR and PSA expressing telomerase established human prostate cancer cell line with neoplastic phenotypes from a primary tumor of a prostate cancer patient.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15375556

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  5 in total

Review 1.  Advancing precision medicine with personalized drug screening.

Authors:  Kirill Gorshkov; Catherine Z Chen; Raisa E Marshall; Nino Mihatov; Yong Choi; Dac-Trung Nguyen; Noel Southall; Kevin G Chen; John K Park; Wei Zheng
Journal:  Drug Discov Today       Date:  2018-08-17       Impact factor: 7.851

2.  The dietary bioflavonoid quercetin synergizes with epigallocathechin gallate (EGCG) to inhibit prostate cancer stem cell characteristics, invasion, migration and epithelial-mesenchymal transition.

Authors:  Su-Ni Tang; Chandan Singh; Dara Nall; Daniel Meeker; Sharmila Shankar; Rakesh K Srivastava
Journal:  J Mol Signal       Date:  2010-08-18

3.  Side population rather than CD133(+) cells distinguishes enriched tumorigenicity in hTERT-immortalized primary prostate cancer cells.

Authors:  Jianjun Zhou; Honghe Wang; Virginetta Cannon; Karen Marie Wolcott; Hongbin Song; Clayton Yates
Journal:  Mol Cancer       Date:  2011-09-14       Impact factor: 27.401

4.  Efficient and simple approach to in vitro culture of primary epithelial cancer cells.

Authors:  Karolina Janik; Marta Popeda; Joanna Peciak; Kamila Rosiak; Maciej Smolarz; Cezary Treda; Piotr Rieske; Ewelina Stoczynska-Fidelus; Magdalena Ksiazkiewicz
Journal:  Biosci Rep       Date:  2016-12-09       Impact factor: 3.840

5.  MicroRNA profiling of novel African American and Caucasian Prostate Cancer cell lines reveals a reciprocal regulatory relationship of miR-152 and DNA methyltranferase 1.

Authors:  Shaniece C Theodore; Melissa Davis; Fu Zhao; Honghe Wang; Dongquan Chen; Johng Rhim; Windy Dean-Colomb; Timothy Turner; Weidong Ji; Guohua Zeng; William Grizzle; Clayton Yates
Journal:  Oncotarget       Date:  2014-06-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.